KPMG supports clients across the worldwide precision medicine ecosystem in their strategic and operational goals, helping them drive top- and bottom-line growth in their businesses. Our ‘one firm’ approach, proprietary data, thought leadership, and deep sector expertise means we can bring unique insights and experience to solve our clients’ most complex business issues.
Precision Medicine is a rapidly evolving market, with technologies such as liquid biopsy, gene therapy, and spatial omic imaging set to change treatment paradigms and improve clinical outcomes for patients. However, this complexity offers unique challenges for life science organizations, as they grapple with the impact across their business - from R&D to supply chain, through to commercialization.
The KPMG Precision Medicine practice is a leader in innovation across all therapeutic areas, in markets around the world. Our comprehensive offerings range from strategic front-end ideation and planning, to commercial, financial, and operational due diligence, and continuing through integration and separation, all fueled by our proprietary precision medicine insights database. See below for more examples of the transformative work we are doing in strategy, deals and operations for all stakeholders in the Precision Medicine ecosystem.
Strategy - What we do
We help our clients solve their most complex strategic problems on a G-LOCAL level – global strategic focus and local level strategy and execution.
Deals - What we do
We support clients from ideation and planning, through all aspects of diligence, and finally through integration and separation.
Operations - What we do
KPMG leverages a holistic approach, helping organizations design and align operating models with business strategy.
Who we work with
Hospitals, Healthcare Systems, and Labs
Biopharma Companies
Diagnostic & Life Science Tools Companies
Private Investors
KPMG’s proprietary Precision Medicine Insight database is used to supplement all our strategy and deals work in this sector worldwide. Survey data is collected annually from molecular pathologists, anatomical pathologists and oncologists in 13 markets, across 4 tumor types: - Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Colorectal Cancer, and Non-Hodgkins Lymphoma (NHL). This data is supplemented by 1-1 qualitative conversations to gain additional insights into how key stakeholders view evolution of the testing landscape and overall Precision Medicine market in the next 5 years.
To understand more about our Precision Medicine Insight database, please contact us.
Example Oncologist Question
Example Pathologist Question
Thought Leadership
See our latest thought leadership
Conferences
Learn more about our Conferences
Podcast and Webcast
Listen to our latest podcasts and webcasts
Industry insights and trends, one click away.